NR2F6 is an orphan nuclear receptor that functions primarily as a transcriptional repressor with critical roles in immune regulation and cancer biology. As an intracellular immune checkpoint, NR2F6 directly represses transcription of key cytokine genes including IL-2, IFN-γ, and TNF-α in T effector cells 1. The receptor serves as an essential gatekeeper of Th17 CD4+ T cell effector functions, acting through a negative feedback loop that limits inflammatory tissue damage induced by weakly immunogenic antigens such as self-antigens 2. Mechanistically, only sustained high-affinity antigen receptor-induced protein kinase C (PKC)-mediated phosphorylation can inactivate NR2F6, displacing it from DNA and allowing robust cytokine transcription 2. In cancer contexts, NR2F6 exhibits tumor-intrinsic functions that regulate antitumor immunity, with genetic ablation conferring more effective responses to PD-1 therapy in melanoma models 3. NR2F6 expression correlates with immunosuppression and poor clinical outcomes in glioma patients, where it promotes recruitment of immunosuppressive cells and M2 macrophage polarization 4. These findings position NR2F6 as a promising therapeutic target for cancer immunotherapy, potentially complementing existing checkpoint inhibitors like CTLA-4 and PD-1 5.